Treatments: Parotid Tumors

A Few Things to Understand First

The parotid glands are the largest of the salivary glands, sitting just in front of and below each ear. The reason parotid tumors require such careful treatment planning is that the facial nerve — the nerve that moves your forehead, eyelids, cheek, and lips — runs directly through the gland, splitting it into a superficial (outer) lobe and a deep (inner) lobe. Protecting this nerve is the single most important goal in almost every parotid operation.

Two facts shape the whole approach to treatment. First, most parotid tumors are benign (non-cancerous), and for these the goal is simply to remove the lump safely and completely. Second, when a tumor is cancerous, treatment is usually a combination of surgery and, in selected cases, radiation or medication — not surgery alone.

Surgery: The Foundation of Treatment

For nearly all parotid tumors that need to be removed, surgery is the main treatment. The operation is called a parotidectomy. Surgeons today think of it as a spectrum, from very limited removal to extensive removal, chosen to match the tumor.

• Extracapsular dissection removes the tumor with just a thin rim of surrounding normal gland, without fully exposing the facial nerve. It is used only for small, mobile, clearly benign tumors in the superficial lobe. In experienced hands it carries lower rates of facial nerve problems and sweating complications than larger operations, with similar cure rates for appropriate tumors.
• Partial superficial parotidectomy removes the tumor plus the portion of the superficial lobe around it. This is the most common operation for benign tumors.
• Superficial (lateral) parotidectomy removes the entire outer lobe after carefully tracing out the whole facial nerve. This was the long-standing standard operation.
• Total parotidectomy removes both the outer and deep lobes while preserving the facial nerve. It is used for deep-lobe tumors and for many cancers.
• Radical parotidectomy removes the gland together with the facial nerve, and is reserved for the uncommon situation where a cancer has grown into or around the nerve itself.

An older technique called enucleation — simply "shelling out" the lump — is not recommended for the most common benign tumor (pleomorphic adenoma) because it leaves tumor behind and leads to high recurrence rates.

Protecting the Facial Nerve

Whenever the facial nerve is working normally before surgery, surgeons work to preserve it, even when a tumor sits right against it. Several tools help:

• Nerve monitoring during the operation, now used routinely, uses small electrodes to signal when the surgeon is near the nerve and lowers the risk of injury.
• Surgeons identify the nerve either by finding its main trunk and following it outward, or by finding a small branch and tracing it back.

If a cancer has already invaded the nerve, or the nerve is found to be encased by tumor, a segment may need to be removed. When that happens, surgeons can often reconstruct the nerve in the same operation — using a nerve graft (commonly borrowed from the neck or leg), transferring a nearby chewing-muscle nerve, or performing other reanimation procedures. Importantly, giving radiation afterward does not ruin a nerve graft, and many patients regain meaningful movement over 1–3 years. Additional procedures, such as a small weight placed in the upper eyelid to help it close, can protect the eye and restore symmetry.

Treating the Neck

Because some cancers spread to lymph nodes, surgery for a parotid cancer may include removal of neck lymph nodes (a neck dissection). This is standard when nodes are already involved, and is often done or recommended for high-grade or larger cancers even when the neck looks normal, because hidden spread is more common in those tumors. Low-grade, small cancers usually do not need it.

Possible Side Effects of Parotid Surgery

Understanding the common after-effects helps set expectations. They include:

• Temporary facial weakness, which is the most common issue and usually recovers over weeks to months. The chance depends on how extensive the surgery is — lower with limited operations and higher with total parotidectomy. Permanent weakness is uncommon, generally in the low single-digit percent range for benign surgery.
• Frey syndrome (gustatory sweating) — sweating or flushing of the cheek when eating — can appear months later. It is caused by nerves that normally stimulated the gland rerouting to skin sweat glands. It can be reduced by placing a tissue barrier at the time of surgery and treated effectively with botulinum toxin (Botox) injections if it occurs.
• Numbness of the earlobe from stretching or cutting a sensory nerve, which is common and often improves but can persist.
• First bite syndrome (a brief sharp pain in the first bite of a meal), a saliva collection or leak that usually settles on its own, and a slight hollowing of the cheek contour that can be reconstructed.

Treating Benign (Non-Cancerous) Tumors

Pleomorphic adenoma — the most common parotid tumor — is usually removed surgically. Although it is benign, it tends to come back if not fully excised, and over many years a small percentage can turn cancerous, which is the main reason removal is advised, especially in younger and healthier patients. With a proper operation, recurrence is low (roughly 2–5%). For selected elderly patients or those with significant other illnesses, careful observation with periodic imaging is a reasonable, shared decision — studies show the health benefit of surgery becomes very small in the oldest age groups.

Warthin tumor — the second most common, strongly linked to smoking — behaves differently. It almost never becomes cancerous (well under 1%), so active surveillance (watch-and-scan) is a widely accepted option, particularly when a needle biopsy has confirmed the diagnosis. In large follow-up studies, very few observed patients ever needed surgery, and no cancers developed. When surgery is chosen, it can often be a more limited operation. Stopping smoking is advised regardless of the path chosen.

Treating Cancerous (Malignant) Parotid Tumors

Treatment of parotid cancer is individualized to the tumor type and grade (described on the Parotid Tumors condition page), its size, and whether it has spread. The general framework is surgery first, followed by radiation in higher-risk cases, with medication reserved mainly for advanced disease.

Surgery

Complete surgical removal, preserving the facial nerve whenever possible, is the cornerstone. More extensive cancers call for total parotidectomy and, often, neck dissection, as described above.

Radiation Therapy

Radiation given after surgery (adjuvant radiation) improves tumor control and is recommended when there are higher-risk features, such as high-grade tumors, cancer at or near the surgical edge, invasion of nerves, spread to lymph nodes, or advanced (large) tumors. Adenoid cystic carcinoma, a type that characteristically tracks along nerves, is generally treated with radiation after surgery even without other risk factors. Modern techniques (such as IMRT) focus the dose and spare surrounding tissue; specialized forms of radiation such as proton or neutron therapy are used in particular situations, mainly for tumors that cannot be removed surgically. For a tumor that cannot be operated on, radiation can be used as the main treatment.

Adding chemotherapy to radiation after surgery is not routine, because it has not been clearly shown to help and may add side effects; a major clinical trial is expected to clarify this question.

Medication (Systemic Therapy)

Medication is used mainly when cancer has spread beyond what surgery and radiation can treat, or has come back. It is typically considered when disease is causing symptoms, threatens an important organ, or is clearly growing. A key modern step is molecular testing of the tumor, which looks for specific targets that matched drugs can attack. Depending on what is found:

• Some aggressive tumors (salivary duct carcinoma) respond to anti-hormone (androgen-blocking) therapy or to HER2-targeted drugs, with meaningful response rates in studies.
• A rare type (secretory carcinoma) often carries an NTRK gene fusion that responds very well to specific targeted pills.
• Immunotherapy has shown only limited benefit in salivary cancers overall and is used selectively.
• Standard chemotherapy has modest effects and is used mainly for symptom control.

Treating Cancers That Spread to the Parotid

The parotid contains lymph nodes, so cancers from the overlying skin can spread there.

For skin squamous cell carcinoma that has reached the parotid, the standard is surgery (parotidectomy plus neck dissection) followed by radiation, which substantially improves control and survival compared with surgery alone. In very high-risk cases, immunotherapy (cemiplimab) after surgery and radiation is now an option, and immunotherapy is also used when the disease cannot be fully removed.

For melanoma that has spread to the parotid, treatment involves parotidectomy with facial-nerve preservation and appropriate neck surgery. Powerful immunotherapy, increasingly given before surgery, has markedly improved outcomes for this group.

Treating Lymphoma of the Parotid

Lymphoma (a cancer of immune cells) in the parotid is treated by blood-cancer specialists, not primarily by surgery — surgery is mainly used to obtain the diagnosis. If lymphoma is confirmed during an operation, the facial nerve is never sacrificed.

The most common type is an indolent (slow-growing) MALT/marginal zone lymphoma, often linked to Sjögren syndrome. When localized, it is highly curable with a modest dose of focused radiation, and most patients do very well. In some cases, the antibody drug rituximab, or careful observation, is appropriate; when the disease is more widespread, rituximab-based treatment is used. A more aggressive lymphoma (diffuse large B-cell lymphoma) is treated with standard chemotherapy-plus-antibody regimens (such as R-CHOP), sometimes with radiation, and outcomes are comparable to the same lymphoma elsewhere in the body.

What You Can Ask Your Care Team

• Is my tumor benign or cancerous, and what is its exact type and grade?
• Is surgery necessary, or is careful observation a reasonable option for me?
• What kind of parotidectomy do you recommend, and what is the chance of temporary or permanent facial weakness?
• Will I need radiation or medication after surgery, and why?
• If part of the facial nerve must be removed, can it be reconstructed in the same operation?
• Who will coordinate my care across surgery, radiation, and oncology?